Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 28, 2017; 23(32): 5913-5924
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5913
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5913
Table 2 Clinicopathologic data for patients with metastatic colorectal cancer n (%)
| Clinicopathologic data | Relapses | De novo metastatic | Total |
| 48 (53.9) | 41 (46.1) | 89 (100) | |
| Age | 65 (40-84.1) | 64 (27-86) | 65 (27-86) |
| Male | 34 (70.8) | 23 (56.1) | 57 (64.8) |
| Primary site | |||
| Colon | 20 (41.7) | 26 (63.4) | 46 (51.7) |
| Rectum | 28 (58.3) | 15 (36.6) | 43 (48.3) |
| Histological grade | |||
| I + II | 27 (56.3) | 28 (68.3) | 55 (61.8) |
| III + IV | 21 (43.7) | 13 (31.7) | 34 (38.2) |
| KRAS mutation | 22 (45.8) | 18 (43.9) | 40 (44.9) |
| BRAF V600E mut | 2 (4.2) | 3 (7.3) | 5 (5.6) |
| TYMS LOH | 15 (31.3) | 11 (26.8) | 26 (29.2) |
| Fluoropyrimidine-based CT | |||
| Monotherapy or with | 5 (10.4) | 5 (12.2) | 10 (11.2) |
| Irinotecan | 18 (37.5) | 10 (24.4) | 28 (31.4) |
| Oxaliplatin | 22 (45.8) | 22 (53.7) | 44 (49.4) |
| Oxaliplatin and irinotecan | 3 (6.3) | 3 (7.3) | 6 (6.7) |
| Bevacizumab | 31 (64.6) | 30 (73.2) | 61 (68.5) |
| No chemotherapy | 0 (0.0) | 1 (2.4) | 1 (1.1) |
| Overall survival | |||
| Deaths | 30 (62.5) | 33 (80.5) | 63 (70.8) |
| Time1 in mo | 21.4 (12.2-30.6) | 18.2 (14.3-22.0) | 19.8 (15.8-23.9) |
| Progression-free survival | |||
| Events | 44 (91.7) | 41 (100.0) | 85 (95.5) |
| Time1 in mo | 10.8 (9.0-12.5) | 9.9 (7.0-12.8) | 10.6 (8.8-12.5) |
| Follow-up in mo | 14.2 (0-72.5) | 17.0 (0.8-119.8) | 14.8 (0-119.8) |
- Citation: Ntavatzikos A, Spathis A, Patapis P, Machairas N, Peros G, Konstantoudakis S, Leventakou D, Panayiotides IG, Karakitsos P, Koumarianou A. Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer. World J Gastroenterol 2017; 23(32): 5913-5924
- URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5913.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i32.5913